BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Go back to BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 8.09 +0.34 (4.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.75 | 52 Week High | $8.73 | |||
| Open | $7.85 | 52 Week Low | $2.86 | |||
| Day High | $8.36 | P/E | N/A | |||
| Day Low | $7.70 | EPS | $-3.82 | |||
| Volume | 940,137 | |||||
